Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.38 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.37 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.36 |
| ▸ | CALCR | P30988 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12314880 | 0.83 | RAMP3 (0.47) | GRB2RAMP3CALCR | |
| SCHEMBL13084700 | 0.83 | RAMP3 (0.47) | GRB2RAMP3CALCR | |
| SCHEMBL12314876 | 0.83 | RAMP3 (0.47) | GRB2RAMP3CALCR | |
| SCHEMBL13084645 | 0.83 | RAMP3 (0.47) | GRB2RAMP3CALCR | |
| SCHEMBL16330316 | 0.77 | RAMP3 (0.45) | GRB2RAMP3CALCR | |
| SCHEMBL12339085 | 0.77 | RAMP3 (0.46) | GRB2CAPN1RAMP3CALCR | |
| SCHEMBL16351204 | 0.77 | RAMP3 (0.46) | GRB2CAPN1RAMP3CALCR | |
| SCHEMBL12899266 | 0.75 | GRB2 (0.50) | GRB2F2NTSR2NTSR1CAPN1 | |
| SCHEMBL12237919 | 0.75 | GRB2 (0.50) | GRB2F2NTSR2NTSR1CAPN1 | |
| SCHEMBL13084631 | 0.75 | GRB2 (0.50) | GRB2F2NTSR2NTSR1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263739-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2012-09-11 | — | — | US | disclosed |